Abnormal activation of lung fibroblasts contributes to the initiation and progression of
idiopathic pulmonary fibrosis (IPF). The objective of the present study was to investigate the role of fetal-lethal noncoding developmental regulatory
RNA (FENDRR) in the activation of lung fibroblasts. Dysregulated long noncoding RNAs in IPF lungs were identified by next-generation sequencing analysis from the two online datasets. FENDRR expression in lung tissues from patients with IPF and mice with
bleomycin-induced
pulmonary fibrosis was determined by quantitative real-time PCR. IRP1 (
iron-responsive
element-
binding protein 1), a
protein partner of FENDRR, was identified by
RNA pulldown-coupled mass spectrometric analysis and confirmed by
RNA immunoprecipitation. The interaction region between FENDRR and IRP1 was determined by cross-linking immunoprecipitation. The in vivo role of FENDRR in
pulmonary fibrosis was studied using adenovirus-mediated gene transfer in mice. The expression of FENDRR was downregulated in fibrotic human and mouse lungs as well as in primary lung fibroblasts isolated from
bleomycin-treated mice. TGF-β1 (transforming growth factor-β1)-SMAD3 signaling inhibited FENDRR expression in lung fibroblasts. FENDRR was preferentially localized in the cytoplasm of adult lung fibroblasts and bound IRP1, suggesting its role in
iron metabolism. FENDRR reduced
pulmonary fibrosis by inhibiting fibroblast activation by reducing
iron concentration and acting as a
competing endogenous RNA of the profibrotic microRNA-214. Adenovirus-mediated FENDRR gene transfer in the mouse lung attenuated
bleomycin-induced lung
fibrosis and improved lung function. Our data suggest that FENDRR is an antifibrotic
long noncoding RNA and a potential therapeutic target for
pulmonary fibrosis.